Portal systemic encephalopathy.
The goal of this article is to update the status of Portal systemic encephalopathy (PSE) in the light of new data. First, PSE is the context of other types of hepatic encephalopathy. Subsequently, current views of the pathogenesis of the disorder are discussed, followed by an analysis of therapeutic options. Diagnosis will not be considered, as no major new developments have recently been documented in this area.
Schenker
S
S
Division of Gastroenterology and Nutrition, The University of Texas Health Science Center at San Antonio, San Antonio, Texas 78282-7878, USA.
Bay
M K
MK
D000641:Ammonia / Q000378:metabolism; D001812:Blood-Brain Barrier; D006501:Hepatic Encephalopathy / Q000209:etiology* / Q000378:metabolism / Q000628:therapy*; D006801:Humans; D007211:Indoles / Q000378:metabolism; D018377:Neurotransmitter Agents / Q000378:metabolism; D019168:Portasystemic Shunt, Transjugular Intrahepatic / Q000009:adverse effects; D013438:Sulfhydryl Compounds / Q000378:metabolism
D007211:Indoles; D018377:Neurotransmitter Agents; D013438:Sulfhydryl Compounds; D000641:Ammonia